# Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

> **NCT00002760** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 260 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ketoconazole
- **DRUG:** therapeutic hydrocortisone
- **OTHER:** Withdrawal of antiandrogen therapy

## Key facts

- **NCT ID:** NCT00002760
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-08
- **Primary completion:** 2004-03
- **Final completion:** 2009-04
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2016-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002760, "Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00002760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*